Search

Your search keyword '"Hugues Charest"' showing total 101 results

Search Constraints

Start Over You searched for: Author "Hugues Charest" Remove constraint Author: "Hugues Charest"
101 results on '"Hugues Charest"'

Search Results

1. The Changing Landscape of Respiratory Viruses Contributing to Hospitalizations in Quebec, Canada: Results From an Active Hospital-Based Surveillance Study

2. A small number of early introductions seeded widespread transmission of SARS-CoV-2 in Québec, Canada

3. Effectiveness of palivizumab immunoprophylaxis to prevent respiratory syncytial virus hospitalizations in healthy full-term

4. SARS-CoV-2 Spike Expression at the Surface of Infected Primary Human Airway Epithelial Cells

5. HIV-1 envelope sequence-based diversity measures for identifying recent infections.

6. HIV-1 Envelope Glycoprotein Amino Acids Signatures Associated with Clade B Transmitted/Founder and Recent Viruses

7. Contagious Period for Pandemic (H1N1) 2009

8. Mid-Season Estimates of Influenza Vaccine Effectiveness against Influenza A(H3N2) Hospitalization in the Elderly in Quebec, Canada, January 2015.

9. HIV-1 Genetic Diversity in Antenatal Cohort, Canada

10. Genomic characterization of a large outbreak of Legionella pneumophila serogroup 1 strains in Quebec City, 2012.

11. Low 2012-13 influenza vaccine effectiveness associated with mutation in the egg-adapted H3N2 vaccine strain not antigenic drift in circulating viruses.

12. A significant reduction in the frequency of HIV-1 drug resistance in Québec from 2001 to 2011 is associated with a decrease in the monitored viral load.

13. Association between the 2008-09 seasonal influenza vaccine and pandemic H1N1 illness during Spring-Summer 2009: four observational studies from Canada.

14. Detection and Sequencing of Multiple Human Norovirus Genotypes from Imported Frozen Raspberries Linked to Outbreaks in the Province of Quebec, Canada, in 2017

15. Vaccine effectiveness estimates from an early-season influenza A(H3N2) epidemic, including unique genetic diversity with reassortment, Canada, 2022/23

16. Persistence of infectivity in elderly individuals diagnosed with severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infection 10 days after onset of symptoms: A cross-sectional study

17. Natural spring water gargle samples as an alternative to nasopharyngeal swabs for SARS‐CoV‐2 detection using a laboratory‐developed test

18. A small number of early introductions seeded widespread transmission of SARS-CoV-2 in Québec, Canada

19. Influenza vaccine effectiveness against A(H3N2) during the delayed 2021/22 epidemic in Canada

20. The changing landscape of respiratory viruses contributing to respiratory hospitalizations: results from a hospital-based surveillance in Quebec, Canada, 2012-13 to 2021-22 (Preprint)

21. The changing landscape of respiratory viruses contributing to respiratory hospitalisations: results from a hospital-based surveillance in Quebec, Canada, 2012-13 to 2021-22

22. Relative Severity of Common Human Coronaviruses and Influenza in Patients Hospitalized With Acute Respiratory Infection: Results From 8-Year Hospital-Based Surveillance in Quebec, Canada

23. An anti-SARS-CoV-2 non-neutralizing antibody with Fc-effector function defines a new NTD epitope and delays neuroinvasion and death in K18-hACE2 mice

24. Impact of temperature on the affinity of SARS-CoV-2 Spike for ACE2

25. A Short-Term Assessment of Nascent HIV-1 Transmission Clusters Among Newly Diagnosed Individuals Using Envelope Sequence-Based Phylogenetic Analyses

26. Infectivity of healthcare workers diagnosed with coronavirus disease 2019 (COVID-19) approximately 2 weeks after onset of symptoms: A cross-sectional study

27. Comparison of SARS-CoV-2 detection from combined nasopharyngeal/oropharyngeal swab samples by a laboratory-developed real-time RT-PCR test and the Roche SARS-CoV-2 assay on a cobas 8800 instrument

28. Real-time PCR-based SARS-CoV-2 detection in Canadian laboratories

29. Influenza Vaccine Does Not Increase the Risk of Coronavirus or Other Noninfluenza Respiratory Viruses: Retrospective Analysis From Canada, 2010–2011 to 2016–2017

30. Interim estimates of 2019/20 vaccine effectiveness during early-season co-circulation of influenza A and B viruses, Canada, February 2020

31. Vaccine Effectiveness Against Lineage-matched and -mismatched Influenza B Viruses Across 8 Seasons in Canada, 2010–2011 to 2017–2018

32. Impact of temperature on the affinity of SARS-CoV-2 Spike glycoprotein for host ACE2

33. Age-Related Differences in Influenza B Infection by Lineage in a Community-Based Sentinel System, 2010–2011 to 2015–2016, Canada

34. Serial Vaccination and the Antigenic Distance Hypothesis: Effects on Influenza Vaccine Effectiveness During A(H3N2) Epidemics in Canada, 2010–2011 to 2014–2015

35. Paradoxical clade- and age-specific vaccine effectiveness during the 2018/19 influenza A(H3N2) epidemic in Canada: potential imprint-regulated effect of vaccine (I-REV)

36. Influenza Vaccine Effectiveness by A(H3N2) Phylogenetic Subcluster and Prior Vaccination History: 2016-2017 and 2017-2018 Epidemics in Canada

37. Phylogenetic analysis of West Nile virus in Quebec, Canada, 2004-2016: Co-circulation of distinct variants harbouring conserved amino acid motifs in North America

38. HIV-1 Envelope Glycoprotein Amino Acids Signatures Associated with Clade B Transmitted/Founder and Recent Viruses

39. Interim estimates of 2018/19 vaccine effectiveness against influenza A(H1N1)pdm09, Canada, January 2019

40. Children under 10 years of age were more affected by the 2018/19 influenza A(H1N1)pdm09 epidemic in Canada: ‎possible cohort effect following the 2009 influenza pandemic

41. Effectiveness of palivizumab immunoprophylaxis to prevent respiratory syncytial virus hospitalizations in healthy full-term <6-month-old infants from the circumpolar region of Nunavik, Quebec, Canada

42. Respiratory syncytial virus contributes to more severe respiratory morbidity than influenza in children 2 years during seasonal influenza peaks

43. Should Sex Be Considered an Effect Modifier in the Evaluation of Influenza Vaccine Effectiveness?

44. Early season co-circulation of influenza A(H3N2) and B(Yamagata): interim estimates of 2017/18 vaccine effectiveness, Canada, January 2018

45. HIV-1 envelope sequence-based diversity measures for identifying recent infections

46. Integrated Sentinel Surveillance Linking Genetic, Antigenic, and Epidemiologic Monitoring of Influenza Vaccine-Virus Relatedness and Effectiveness During the 2013–2014 Influenza Season

47. Interim estimates of 2016/17 vaccine effectiveness against influenza A(H3N2), Canada, January 2017

48. Influenza A/Subtype and B/Lineage Effectiveness Estimates for the 2011–2012 Trivalent Vaccine: Cross-Season and Cross-Lineage Protection With Unchanged Vaccine

49. Temporal Changes in Pediatric Gastroenteritis after Rotavirus Vaccination in Quebec

50. A Sentinel Platform to Evaluate Influenza Vaccine Effectiveness and New Variant Circulation, Canada 2010–2011 Season

Catalog

Books, media, physical & digital resources